厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较

摘要

<正>1文献来源Zhong WZ,Wu YL,Chen KN,et al. CTONG1103:Erlotinib versus Gemcitabine plus Cisplatin as neoadjuvant treatment for stage ⅢA-N2 EGFR-mutation positive non-small-cell lung cancer(EMERGING):A randomised study[J]. Ann Oncol,2018,29(8S):LBA48PR.2证据水平1b。3背景·ⅢA-N2期非小细胞肺癌(non-small-celllung cancer,NSCLC)具有相当大的异质性,根据同侧纵隔淋巴结受累程度不同分为ⅢA1～ⅢA4

关键词